Implementation of Upstream Intensified Manufacturing Strategies
Process Intensification enables you to address the current trends exerting pressure on the biopharmaceutical industry. With the drive to maximize facility utilization, increase facility throughput, and create multi-product capability, there is a need to implement perfusion or enhanced fed-batch approaches.
Upstream solutions like Ambr® 15, Ambr® 250, Biostat® RM, and Biostat STR® enable you to scale from high throughput process development to different seed train and manufacturing scenarios using fed-batch, intensified, or perfusion cultures. You can further enhance process monitoring and control using various integrated Process Analytical Technologies (PAT).
Why is the Industry Moving Towards Intensified Processing?
An interview with Miriam Monge on Bioprocess Intensification at CPhI in Frankfurt 2019, talking about the strong focus the industry has on intensified and continuous processing, current standards, biosimilars and the solutions Sartorius is offering, including a look into 2020. > Full FINAL VERSION without SUBTITLE
Miriam Monge talks about the significance of intensified processing and the most exciting Sartorius developments for 2020 and beyond. Watch this interview to stay posted.
Single-Use and Intensified Processing in Commercial Biomanufacturing
How do single-use facilities influence cost of goods in biopharmaceutical manufacturing and what regulatory issues still surround the implementation of single-use technologies? Watch Miriam Monge and Gerben Zijlstra in discussion with Dan Stanton, Editor of Bioprocess Insider.
